Tuberculosis in sub-Saharan Africa: opportunities, challenges, and change in the era of antiretroviral treatment

[1]  S. Ferebee,et al.  Tuberculosis morbidity in a controlled trial of the prophylactic use of isoniazid among household contacts. , 2015, The American review of respiratory disease.

[2]  S. Strathdee,et al.  Adherence to Antiretroviral Therapy Among HIV-Infected Drug Users: A Meta-Analysis , 2010, AIDS and Behavior.

[3]  Rony Zachariah,et al.  Reasons for loss to follow-up among mothers registered in a prevention-of-mother-to-child transmission program in rural Malawi. , 2008, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[4]  Julio S. G. Montaner,et al.  CD4+ T-Cell Count Monitoring Does Not Accurately Identify HIV-Infected Adults With Virologic Failure Receiving Antiretroviral Therapy , 2008, Journal of acquired immune deficiency syndromes.

[5]  Richard D Moore,et al.  Recurrent tuberculosis in HIV-infected patients in Rio de Janeiro, Brazil , 2008, AIDS.

[6]  N. McGrath,et al.  Individual, household and community factors associated with HIV test refusal in rural Malawi , 2008, Tropical medicine & international health : TM & IH.

[7]  M. Carrieri,et al.  The impact of methadone or buprenorphine treatment and ongoing injection on highly active antiretroviral therapy (HAART) adherence: evidence from the MANIF2000 cohort study. , 2008, Addiction.

[8]  R. Mattick,et al.  Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review , 2008, The Lancet.

[9]  Richard D Moore,et al.  Rate of comorbidities not related to HIV infection or AIDS among HIV-infected patients, by CD4 cell count and HAART use status. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  Qilong Yi,et al.  Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis , 2008, AIDS.

[11]  P. Mee,et al.  Evaluation of the WHO criteria for antiretroviral treatment failure among adults in South Africa , 2008, AIDS.

[12]  S. Lewin,et al.  A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naïve individuals in Thailand , 2008, Hepatology.

[13]  B. Chi,et al.  A Pilot Study of Food Supplementation to Improve Adherence to Antiretroviral Therapy Among Food-Insecure Adults in Lusaka, Zambia , 2008, Journal of acquired immune deficiency syndromes.

[14]  B. Eley,et al.  Provision of antiretroviral therapy to children within the public sector of South Africa. , 2008, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[15]  V. Arendt,et al.  Efavirenz in Human Breast Milk, Mothers', and Newborns' Plasma , 2008, Journal of acquired immune deficiency syndromes.

[16]  C. Kilewo,et al.  Prevention of Mother-to-Child Transmission of HIV-1 Through Breast-Feeding by Treating Infants Prophylactically With Lamivudine in Dar es Salaam, Tanzania: The Mitra Study , 2008, Journal of acquired immune deficiency syndromes.

[17]  W M Tierney,et al.  Patterns of care in two HIV continuity clinics in Uganda, Africa: a time-motion study , 2008, AIDS care.

[18]  P. Simon,et al.  HIV Risk Factors Reported by Two Samples of Male Bathhouse Attendees in Los Angeles, California, 2001–2002 , 2008, Sexually transmitted diseases.

[19]  J. Nachega,et al.  Pharmacy Refill Adherence Compared with CD4 Count Changes for Monitoring HIV-Infected Adults on Antiretroviral Therapy , 2008, PLoS medicine.

[20]  J. Gatell,et al.  Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study. , 2008, The Journal of infectious diseases.

[21]  O. Minzi,et al.  Validation of self-report and hospital pill count using unannounced home pill count as methods for determination of adherence to antiretroviral therapy. , 2008, Tanzania journal of health research.

[22]  J. Peto,et al.  Current CD4 cell count and the short-term risk of AIDS and death before the availability of effective antiretroviral therapy in HIV-infected children and adults. , 2008, The Journal of infectious diseases.

[23]  N. Ford,et al.  Implementing antiretroviral therapy in rural communities: the Lusikisiki model of decentralized HIV/AIDS care. , 2007, The Journal of infectious diseases.

[24]  R. Salamon,et al.  Incidence and determinants of mortality and morbidity following early antiretroviral therapy initiation in HIV-infected adults in West Africa , 2007, AIDS.

[25]  J. Rich,et al.  A model of integrated primary care for HIV-positive patients with underlying substance use and mental illness , 2007, AIDS care.

[26]  B. Masquelier,et al.  Prevalence of resistance to nevirapine in mothers and children after single-dose exposure to prevent vertical transmission of HIV-1: a meta-analysis. , 2007, International journal of epidemiology.

[27]  D. Walque.  Sero‐Discordant Couples in Five African Countries: Implications for Prevention Strategies , 2007 .

[28]  W. El-Sadr,et al.  Nevirapine‐associated toxicity in HIV‐infected Thai men and women, including pregnant women , 2007, HIV medicine.

[29]  R. Chaiwarith,et al.  Sensitivity and specificity of using CD4+ measurement and clinical evaluation to determine antiretroviral treatment failure in Thailand. , 2007, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[30]  JD Lundgren,et al.  Normalisation of CD4 counts in patients with HIV-1 infection and maximum virological suppression who are taking combination antiretroviral therapy: an observational cohort study , 2007, The Lancet.

[31]  Richard D Moore,et al.  The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil , 2007, AIDS.

[32]  L. Koenig,et al.  Trends in Opportunistic Infections in the Pre–and Post–Highly Active Antiretroviral Therapy Eras Among HIV-Infected Children in the Perinatal AIDS Collaborative Transmission Study, 1986–2004 , 2007, Pediatrics.

[33]  A. Zolopa,et al.  Effect of Concomitantly Administered Rifampin on the Pharmacokinetics and Safety of Atazanavir Administered Twice Daily , 2007, Antimicrobial Agents and Chemotherapy.

[34]  C. Fraser,et al.  CD4 Cell Counts of 800 Cells/mm3 or Greater After 7 Years of Highly Active Antiretroviral Therapy Are Feasible in Most Patients Starting With 350 Cells/mm3 or Greater , 2007, Journal of acquired immune deficiency syndromes.

[35]  J. Hitti,et al.  Antiretroviral-Associated Toxicity Among HIV-1-Seropositive Pregnant Women in Mozambique Receiving Nevirapine-Based Regimens , 2007, Journal of acquired immune deficiency syndromes.

[36]  S. Kalichman,et al.  Adherence to Antiretroviral Therapy Assessed by Unannounced Pill Counts Conducted by Telephone , 2007, Journal of General Internal Medicine.

[37]  S. Lai,et al.  HIV Incidence, Retention, and Changes of High-Risk Behaviors Among Rural Injection Drug Users in Guangxi, China , 2007, Substance abuse.

[38]  K. Kam,et al.  Establishing CD4 thresholds for highly active antiretroviral therapy initiation in a cohort of HIV-infected adult Chinese in Hong Kong. , 2007, AIDS patient care and STDs.

[39]  S. Lagakos,et al.  Response to antiretroviral therapy after a single, peripartum dose of nevirapine. , 2007, The New England journal of medicine.

[40]  S. Lawn,et al.  Conservation of First-Line Antiretroviral Treatment Regimen where Therapeutic Options are Limited , 2007, Antiviral therapy.

[41]  S. Zeichner,et al.  Patient, Caregiver and Regimen Characteristics Associated With Adherence to Highly Active Antiretroviral Therapy Among HIV-Infected Children and Adolescents , 2007, The Pediatric infectious disease journal.

[42]  I. Buchan,et al.  Adherence to HAART: A Systematic Review of Developed and Developing Nation Patient-Reported Barriers and Facilitators , 2006, PLoS medicine.

[43]  R. Bertz,et al.  Effect of Rifampin on Steady-State Pharmacokinetics of Atazanavir with Ritonavir in Healthy Volunteers , 2006, Antimicrobial Agents and Chemotherapy.

[44]  O. Kirk,et al.  Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. , 2006, Archives of internal medicine.

[45]  C Inch,et al.  Patient support and education for promoting adherence to highly active antiretroviral therapy for HIV/AIDS. , 2006, The Cochrane database of systematic reviews.

[46]  R. Hayes,et al.  Uptake of Workplace HIV Counselling and Testing: A Cluster-Randomised Trial in Zimbabwe , 2006, PLoS medicine.

[47]  A. Earnest,et al.  The impact of malnutrition on survival and the CD4 count response in HIV‐infected patients starting antiretroviral therapy , 2006, HIV Medicine.

[48]  Richard D Moore,et al.  Directly administered antiretroviral therapy in methadone clinics is associated with improved HIV treatment outcomes, compared with outcomes among concurrent comparison groups. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[49]  N. Walker,et al.  Improved plausibility bounds about the 2005 HIV and AIDS estimates , 2006, Sexually Transmitted Infections.

[50]  M. Johnson,et al.  96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures , 2006, AIDS.

[51]  P. Pezzotti,et al.  Comparing costs and effectiveness of different starting points for highly active antiretroviral therapy in HIV-positive patients , 2006, The European Journal of Health Economics.

[52]  T. Coates,et al.  Removing Barriers to Knowing HIV Status: Same-Day Mobile HIV Testing in Zimbabwe , 2006, Journal of acquired immune deficiency syndromes.

[53]  S. Steinberg,et al.  Tenofovir Disoproxil Fumarate and an Optimized Background Regimen of Antiretroviral Agents as Salvage Therapy for Pediatric HIV Infection , 2005, Pediatrics.

[54]  M. Notha,et al.  Antituberculosis drug resistance and anonymous HIV surveillance in tuberculosis patients in Botswana, 2002 , 2005, The Lancet.

[55]  A. Muir,et al.  HIV coinfection shortens the survival of patients with hepatitis C virus–related decompensated cirrhosis , 2005, Hepatology.

[56]  S. Lawn,et al.  How effectively does HAART restore immune responses to Mycobacterium tuberculosis? Implications for tuberculosis control , 2005, AIDS.

[57]  N. Daniels.  Fair process in patient selection for antiretroviral treatment in WHO's goal of 3 by 5 , 2005, The Lancet.

[58]  B. Marston,et al.  The sound of one hand clapping: tuberculosis and antiretroviral therapy in Africa. , 2005, American journal of respiratory and critical care medicine.

[59]  E. Messou,et al.  Risk factors for active tuberculosis after antiretroviral treatment initiation in Abidjan. , 2005, American journal of respiratory and critical care medicine.

[60]  S. Munyati,et al.  Chronic cough in primary health care attendees, Harare, Zimbabwe: diagnosis and impact of HIV infection. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[61]  P. Morlat,et al.  Liver disease as a major cause of death among HIV infected patients: role of hepatitis C and B viruses and alcohol. , 2005, Journal of hepatology.

[62]  S. Lawn,et al.  Immune reconstitution disease associated with mycobacterial infections in HIV-infected individuals receiving antiretrovirals. , 2005, The Lancet. Infectious diseases.

[63]  C. F. von Reyn,et al.  High rates of clinical and subclinical tuberculosis among HIV-infected ambulatory subjects in Tanzania. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[64]  A. Mocroft,et al.  Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort , 2005, AIDS.

[65]  M. Gill,et al.  Changing mortality rates and causes of death for HIV‐infected individuals living in Southern Alberta, Canada from 1984 to 2003 , 2005, HIV medicine.

[66]  B. Wolff,et al.  Evaluation of a home-based voluntary counselling and testing intervention in rural Uganda. , 2005, Health policy and planning.

[67]  A. Harries,et al.  Can we get more HIV-positive tuberculosis patients on antiretroviral treatment in a rural district of Malawi? , 2005, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[68]  C. Dye,et al.  Tuberculosis deaths in countries with high HIV prevalence: what is their use as an indicator in tuberculosis programme monitoring and epidemiological surveillance? , 2005, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[69]  A. Harries,et al.  Human resources for control of tuberculosis and HIV-associated tuberculosis. , 2005, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[70]  A. Sturm,et al.  Effectiveness of cotrimoxazole prophylaxis on mortality in adults with tuberculosis in rural South Africa , 2005, AIDS.

[71]  Pam Sonnenberg,et al.  How soon after infection with HIV does the risk of tuberculosis start to increase? A retrospective cohort study in South African gold miners. , 2005, The Journal of infectious diseases.

[72]  A. Harries,et al.  Monitoring the response to antiretroviral therapy in resource-poor settings: the Malawi model. , 2004, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[73]  M. Jacobs,et al.  Human resources for health: overcoming the crisis , 2004, The Lancet.

[74]  R. Chaisson,et al.  Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis. , 2004, American journal of respiratory and critical care medicine.

[75]  R. Quick,et al.  Effect of co-trimoxazole prophylaxis on morbidity, mortality, CD4-cell count, and viral load in HIV infection in rural Uganda , 2004, The Lancet.

[76]  Nigel Rollins,et al.  Mortality of infected and uninfected infants born to HIV-infected mothers in Africa: a pooled analysis , 2004, The Lancet.

[77]  A. Nunn,et al.  Two 8-month regimens of chemotherapy for treatment of newly diagnosed pulmonary tuberculosis: international multicentre randomised trial , 2004, The Lancet.

[78]  H. Whittle,et al.  Body Mass Index at Time of HIV Diagnosis: A Strong and Independent Predictor of Survival , 2004, Journal of acquired immune deficiency syndromes.

[79]  R. Hayes,et al.  Human immunodeficiency virus and the prevalence of undiagnosed tuberculosis in African gold miners. , 2004, American journal of respiratory and critical care medicine.

[80]  S. Twu,et al.  Decreased HIV transmission after a policy of providing free access to highly active antiretroviral therapy in Taiwan. , 2004, The Journal of infectious diseases.

[81]  R. Teck,et al.  Implementing joint TB and HIV interventions in a rural district of Malawi: is there a role for an international non-governmental organisation? , 2004, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[82]  M. Borgdorff,et al.  New Measurable Indicator for Tuberculosis Case Detection , 2004, Emerging infectious diseases.

[83]  R. Chaisson,et al.  Hepatotoxicity of rifampin and pyrazinamide in the treatment of latent tuberculosis infection in HIV-infected persons: is it different than in HIV-uninfected persons? , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[84]  K. Schwartzman,et al.  Treatment completion and costs of a randomized trial of rifampin for 4 months versus isoniazid for 9 months. , 2004, American journal of respiratory and critical care medicine.

[85]  W. El-Sadr,et al.  A Pilot Study of Once-Daily Antiretroviral Therapy Integrated With Tuberculosis Directly Observed Therapy in a Resource-Limited Setting , 2004, Journal of acquired immune deficiency syndromes.

[86]  P. van der Stuyft,et al.  Accuracy of routine diagnosis of pulmonary tuberculosis in an area of high HIV prevalence. , 2004, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[87]  Katharina Kober,et al.  Scaling up access to antiretroviral treatment in southern Africa: who will do the job? , 2004, The Lancet.

[88]  M. Borgdorff,et al.  Trends in tuberculosis and the influence of HIV infection in northern Malawi, 1988-2001. , 2004, AIDS.

[89]  A. Crampin,et al.  Trends in tuberculosis and the influence of HIV infection in northern Malawi, 1988–2001 , 2004, AIDS.

[90]  A. Harries,et al.  Long-term outcome in patients registered with tuberculosis in Zomba, Malawi: mortality at 7 years according to initial HIV status and type of TB. , 2004, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[91]  V. Diwan,et al.  Should the 'bleach microscopy method' be recommended for improved case detection of tuberculosis? Literature review and key person analysis. , 2004, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[92]  W. Fawzi,et al.  Late postnatal transmission of HIV-1 in breast-fed children: an individual patient data meta-analysis. , 2004, The Journal of infectious diseases.

[93]  Felipe García,et al.  Long-Term CD4+ T-Cell Response to Highly Active Antiretroviral Therapy According to Baseline CD4+ T-Cell Count , 2004, Journal of acquired immune deficiency syndromes.

[94]  U. Lalloo,et al.  Utility of tuberculosis directly observed therapy programs as sites for access to and provision of antiretroviral therapy in resource-limited countries. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[95]  Eric Goemaere,et al.  Integrating tuberculosis and HIV care in the primary care setting in South Africa , 2004, Tropical medicine & international health : TM & IH.

[96]  L. Bekker,et al.  Initiating highly active antiretroviral therapy in sub-Saharan Africa: an assessment of the revised World Health Organization scaling-up guidelines , 2004, AIDS.

[97]  C. Horsburgh.  Priorities for the treatment of latent tuberculosis infection in the United States. , 2004, The New England journal of medicine.

[98]  R. Bertz,et al.  Pharmacokinetics of Adjusted-Dose Lopinavir-Ritonavir Combined with Rifampin in Healthy Volunteers , 2004, Antimicrobial Agents and Chemotherapy.

[99]  A. Crampin,et al.  Cotrimoxazole prophylaxis reduces mortality in human immunodeficiency virus-positive tuberculosis patients in Karonga District, Malawi. , 2004, Bulletin of the World Health Organization.

[100]  A. Harries,et al.  Voluntary counselling, HIV testing and adjunctive cotrimoxazole are associated with improved TB treatment outcomes under routine conditions in Thyolo District, Malawi. , 2004, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[101]  J. Macías,et al.  Effect of antiretroviral drugs on liver fibrosis in HIV-infected patients with chronic hepatitis C: harmful impact of nevirapine , 2004, AIDS.

[102]  C. Kuaban,et al.  Are smear-positive pulmonary tuberculosis patients a 'sentinel' population for the HIV epidemic in Cameroon? , 2004, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[103]  R. Chaisson,et al.  Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis. , 2004, American journal of respiratory and critical care medicine.

[104]  N. Klitgaard,et al.  Pharmacokinetic interaction between rifampin and the combination of indinavir and low-dose ritonavir in HIV-infected patients. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[105]  P. Small,et al.  Clinical management of tuberculosis in the context of HIV infection. , 2004, Annual review of medicine.

[106]  Paul R Klatser,et al.  A comprehensive comparison of Ziehl-Neelsen and fluorescence microscopy for the diagnosis of tuberculosis in a resource-poor urban setting. , 2003, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[107]  Ej Lee,et al.  Value of chest radiography in a tuberculosis prevention programme for HIV-infected people, Botswana , 2003, The Lancet.

[108]  Christopher Dye,et al.  Tuberculosis epidemics driven by HIV: is prevention better than cure? , 2003, AIDS.

[109]  Brian G. Williams,et al.  Tuberculosis epidemics driven by HIV , 2003 .

[110]  R. Hayes,et al.  Stable incidence rates of tuberculosis (TB) among human immunodeficiency virus (HIV)-negative South African gold miners during a decade of epidemic HIV-associated TB. , 2003, The Journal of infectious diseases.

[111]  R. Chaisson,et al.  Efficacy of secondary isoniazid preventive therapy among HIV-infected Southern Africans: time to change policy? , 2003, AIDS.

[112]  Brian G. Williams,et al.  Antiretroviral Drugs for Tuberculosis Control in the Era of HIV/AIDS , 2003, Science.

[113]  D. Mayers,et al.  A Comprehensive Hepatic Safety Analysis of Nevirapine in Different Populations of HIV Infected Patients* , 2003, Journal of acquired immune deficiency syndromes.

[114]  Robert L. Johnson,et al.  Case finding for HIV-positive youth: a special type of hidden population. , 2003, The Journal of adolescent health : official publication of the Society for Adolescent Medicine.

[115]  C. Dye,et al.  Effects of human immunodeficiency virus infection on recurrence of tuberculosis after rifampin-based treatment: an analytical review. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[116]  Christopher Dye,et al.  The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. , 2003, Archives of internal medicine.

[117]  A. Harries,et al.  Voluntary counselling, HIV testing and adjunctive cotrimoxazole reduces mortality in tuberculosis patients in Thyolo, Malawi , 2003, AIDS.

[118]  D. Hoover,et al.  Use-Effectiveness of the Female Versus Male Condom in Preventing Sexually Transmitted Disease in Women , 2003, Sexually transmitted diseases.

[119]  Kamran Siddiqi,et al.  Clinical diagnosis of smear-negative pulmonary tuberculosis in low-income countries: the current evidence. , 2003, The Lancet. Infectious diseases.

[120]  Roger Detels,et al.  When to initiate highly active antiretroviral therapy: a cohort approach. , 2003, American journal of epidemiology.

[121]  Maria Deloria-Knoll,et al.  Survival Benefit of Initiating Antiretroviral Therapy in HIV-Infected Persons in Different CD4+ Cell Strata , 2003, Annals of Internal Medicine.

[122]  P. van der Stuyft,et al.  A comparison of direct microscopy, the concentration method and the Mycobacteria Growth Indicator Tube for the examination of sputum for acid-fast bacilli. , 2003, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[123]  A. Moscicki,et al.  Barriers to HAART adherence among human immunodeficiency virus-infected adolescents. , 2003, Archives of pediatrics & adolescent medicine.

[124]  C. Sabin,et al.  Short-term CD4 cell response after highly active antiretroviral therapy initiated at different times from seroconversion in 1,500 seroconverters. , 2003, Journal of acquired immune deficiency syndromes.

[125]  A. Fernández-Villar,et al.  Isoniazid hepatotoxicity among drug users: the role of hepatitis C. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[126]  P. Klatser,et al.  A comprehensive study of the efficiency of the routine pulmonary tuberculosis diagnostic process in Nairobi. , 2003, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[127]  Jeffrey N. Martin,et al.  Decline in HIV infectivity following the introduction of highly active antiretroviral therapy , 2003, AIDS.

[128]  Else Smith.  [Condom effectiveness in reducing heterosexual HIV transmission]. , 2002, Ugeskrift for laeger.

[129]  E. Vittinghoff,et al.  Short-Course Rifampin and Pyrazinamide Compared with Isoniazid for Latent Tuberculosis Infection: A Multicenter Clinical Trial , 2002, Annals of Internal Medicine.

[130]  H. Yanai,et al.  The Evolving Epidemiology of HIV Infection and Tuberculosis in Northern Thailand , 2002, Journal of acquired immune deficiency syndromes.

[131]  F. Drobniewski,et al.  A national study of clinical and laboratory factors affecting the survival of patients with multiple drug resistant tuberculosis in the UK , 2002, Thorax.

[132]  R. Chaisson,et al.  Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial , 2002, The Lancet.

[133]  COST-EFFECTIVENESS IMPLICATIONS OF THE TIMING OF ANTIRETROVIRAL THERAPY IN HIV-INFECTED ADULTS , 2002 .

[134]  Jonathan AC Sterne,et al.  Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies , 2002, The Lancet.

[135]  Elizabeth Marum,et al.  Shadow on the continent: public health and HIV/AIDS in Africa in the 21st century , 2002, The Lancet.

[136]  R. Weber,et al.  Clinical efficacy of early initiation of HAART in patients with asymptomatic HIV infection and CD4 cell count > 350 × 106/l , 2002, AIDS.

[137]  R. Wood,et al.  Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study , 2002, The Lancet.

[138]  C. Dye,et al.  Feasibility and cost-effectiveness of standardised second-line drug treatment for chronic tuberculosis patients: a national cohort study in Peru , 2002, The Lancet.

[139]  M. Reichler,et al.  Treatment of Latent Tuberculosis Infection in Contacts of New Tuberculosis Cases in the United States , 2002, Southern medical journal.

[140]  K. Floyd,et al.  Resources Required for Global Tuberculosis Control , 2002, Science.

[141]  J. Dilley,et al.  Impact of highly active antiretroviral treatment on HIV seroincidence among men who have sex with men: San Francisco. , 2002, American journal of public health.

[142]  L. Harrison,et al.  Reduced risk of tuberculosis among Brazilian patients with advanced human immunodeficiency virus infection treated with highly active antiretroviral therapy. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[143]  A. Cavaliere,et al.  Periconceptional exposure to efavirenz and neural tube defects. , 2002, Archives of internal medicine.

[144]  P. Martín-Dávila,et al.  Paradoxical reactions of tuberculosis in patients with the acquired immunodeficiency syndrome who are treated with highly active antiretroviral therapy. , 2002, Archives of internal medicine.

[145]  N. Ives,et al.  Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy , 2002, AIDS.

[146]  R. Chaisson,et al.  Hepatotoxicity associated with nevirapine or efavirenz‐containing antiretroviral therapy: Role of hepatitis C and B infections , 2002, Hepatology.

[147]  I. Ocaña,et al.  Pharmacokinetic interaction between nevirapine and rifampicin in HIV-infected patients with tuberculosis. , 2001, Journal of acquired immune deficiency syndromes.

[148]  A. Harries,et al.  Design of regimens for treating tuberculosis in patients with HIV infection, with particular reference to sub-Saharan Africa. , 2001, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[149]  R Weber,et al.  HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load. , 2001, JAMA.

[150]  P. Sonnenberg,et al.  HIV-1 and recurrence, relapse, and reinfection of tuberculosis after cure: a cohort study in South African mineworkers , 2001, The Lancet.

[151]  D. Vlahov,et al.  Isoniazid preventive therapy, hepatitis C virus infection, and hepatotoxicity among injection drug users infected with Mycobacterium tuberculosis. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[152]  L. Harrison,et al.  Chemoprophylaxis for tuberculosis and survival of HIV-infected patients in Brazil , 2001, AIDS.

[153]  John L. Johnson,et al.  Duration of efficacy of treatment of latent tuberculosis infection in HIV-infected adults , 2001, AIDS.

[154]  Glynn,et al.  Comparison of two versus three smears in identifying culture-positive tuberculosis patients in a rural African setting with high HIV prevalence. , 2001, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[155]  F. Mostashari,et al.  Trust and the Acceptance of and Adherence to Antiretroviral Therapy , 2001, Journal of acquired immune deficiency syndromes.

[156]  C. Whitty,et al.  'Smear-negative' pulmonary tuberculosis in a DOTS programme: poor outcomes in an area of high HIV seroprevalence. , 2001, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[157]  M. Hirsch,et al.  Prevalence and predictive value of intermittent viremia with combination hiv therapy. , 2001, JAMA.

[158]  W. Burman,et al.  Treatment of HIV-related tuberculosis in the era of effective antiretroviral therapy. , 2001, American journal of respiratory and critical care medicine.

[159]  J. Hackman,et al.  A randomized, controlled trial of interventions to improve adherence to isoniazid therapy to prevent tuberculosis in injection drug users. , 2001, The American journal of medicine.

[160]  M. Moroni,et al.  When to start highly active antiretroviral therapy in chronically HIV-infected patients: evidence from the ICONA study , 2001, AIDS.

[161]  Christopher Dye,et al.  Global trends in resistance to antituberculosis drugs. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance. , 2001, The New England journal of medicine.

[162]  G. Ippolito,et al.  Changing Clinical Presentation and Survival in HIV‐Associated Tuberculosis After Highly Active Antiretroviral Therapy , 2001, Journal of acquired immune deficiency syndromes.

[163]  K. Mcintosh,et al.  Trial of Shortened Zidovudine Regimens to Prevent Mother-to-Child Transmission of Human Immunodeficiency Virus Type 1 , 2001 .

[164]  S. Lockman,et al.  Molecular and Conventional Epidemiology ofMycobacterium tuberculosis in Botswana: a Population-Based Prospective Study of 301 Pulmonary Tuberculosis Patients , 2001, Journal of Clinical Microbiology.

[165]  D. Murphy,et al.  Antiretroviral medication adherence among the REACH HIV-infected adolescent cohort in the USA , 2001, AIDS care.

[166]  A. Harries,et al.  What causes smear-negative pulmonary tuberculosis in Malawi, an area of high HIV seroprevalence? , 2001, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[167]  D. Fuchs,et al.  Long-term effect of preventive therapy for tuberculosis in a cohort of HIV-infected Zambian adults , 2001, AIDS.

[168]  A. Harries,et al.  Tuberculosis case fatality rates in high HIV prevalence populations in sub-Saharan Africa , 2001, AIDS.

[169]  Yukari C. Manabe,et al.  Latent Mycobacterium tuberculosis–persistence, patience, and winning by waiting , 2000, Nature Medicine.

[170]  A. DeMaria,et al.  Adherence to medication regimens among children with human immunodeficiency virus infection , 2000, The Pediatric infectious disease journal.

[171]  R. Hayes,et al.  HIV infection and silicosis: the impact of two potent risk factors on the incidence of mycobacterial disease in South African miners , 2000, AIDS.

[172]  Jeffrey L. Jones,et al.  HIV-associated tuberculosis in the era of highly active antiretroviral therapy. The Adult/Adolescent Spectrum of HIV Disease Group. , 2000, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[173]  P. Sonnenberg,et al.  Tuberculosis control and molecular epidemiology in a South African gold-mining community , 2000, The Lancet.

[174]  G. Ippolito,et al.  Impact of combination antiretroviral therapy on the risk of tuberculosis among persons with HIV infection , 2000, AIDS.

[175]  E. Vittinghoff,et al.  Home collection for frequent HIV testing: acceptability of oral fluids, dried blood spots and telephone results , 2000, AIDS.

[176]  F. Donato,et al.  Mortality for liver disease in patients with HIV infection: a cohort study. , 2000, Journal of acquired immune deficiency syndromes.

[177]  M. Bosman.  Health sector reform and tuberculosis control: the case of Zambia. , 2000, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[178]  I. Kleinschmidt,et al.  The impact of HIV infection on recurrence of tuberculosis in South African gold miners. , 2000, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[179]  C. Power,et al.  Autopsy study of HIV-1-positive and HIV-1-negative adult medical patients in Nairobi, Kenya. , 2000 .

[180]  M. Wainberg,et al.  The M184V Mutation in the Reverse Transcriptase of Human Immunodeficiency Virus Type 1 Impairs Rescue of Chain-Terminated DNA Synthesis , 2000, Journal of Virology.

[181]  J. Scott,et al.  Aetiology, outcome, and risk factors for mortality among adults with acute pneumonia in Kenya , 2000, The Lancet.

[182]  M. Lindegren,et al.  Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[183]  I. Bastian,et al.  A review of the diagnosis and treatment of smear-negative pulmonary tuberculosis. , 2000, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[184]  G. Comstock.  How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults? , 1999, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[185]  C. Katlama,et al.  Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients , 1999, Hepatology.

[186]  I. Kleinschmidt,et al.  Mycobacterial disease in South African gold miners in the era of HIV infection. , 1999, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[187]  N. Nagelkerke,et al.  Tuberculosis and the HIV epidemic: increasing annual risk of tuberculous infection in Kenya, 1986-1996. , 1999, American journal of public health.

[188]  De Cock Km,et al.  Will DOTS do it? A reappraisal of tuberculosis control in countries with high rates of HIV infection. , 1999 .

[189]  J. Karon,et al.  Efficacy of trimethoprim-sulphamethoxazole prophylaxis to decrease morbidity and mortality in HIV-1-infected patients with tuberculosis in Abidjan, Côte d'Ivoire: a randomised controlled trial , 1999, The Lancet.

[190]  M. Grayson,et al.  Isoniazid toxicity in health care workers. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[191]  S. Buskin,et al.  Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic. , 1999, JAMA.

[192]  G H Guyatt,et al.  Isoniazid prophylaxis for tuberculosis in HIV infection: a meta-analysis of randomized controlled trials. , 1999, AIDS.

[193]  J. Porter,et al.  Twice weekly tuberculosis preventive therapy in HIV infection in Zambia , 1998, AIDS.

[194]  J. Fitzgerald,et al.  Acceptance and safety of directly observed versus self-administered isoniazid preventive therapy in aboriginal peoples in British Columbia. , 1998, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[195]  P. Garner,et al.  Effect of preventive treatment for tuberculosis in adults infected with HIV: systematic review of randomised placebo controlled trials , 1998, BMJ.

[196]  M. Bachmann,et al.  Block appointments in an overloaded South African health centre: quantitative and qualitative evaluation. , 1998, International journal of health care quality assurance incorporating Leadership in health services.

[197]  J. Paul,et al.  Chronic diarrhoea among HIV-infected adult patients in Nairobi, Kenya , 1998, Journal of Infection.

[198]  A. Albanese,et al.  Antituberculosis drug-induced hepatotoxicity. The role of hepatitis C virus and the human immunodeficiency virus. , 1998, American journal of respiratory and critical care medicine.

[199]  John L. Johnson,et al.  Impact of human immunodeficiency virus type-1 infection on the initial bacteriologic and radiographic manifestations of pulmonary tuberculosis in Uganda. Makerere University-Case Western Reserve University Research Collaboration. , 1998, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[200]  I. Onorato,et al.  An outbreak involving extensive transmission of a virulent strain of Mycobacterium tuberculosis. , 1998, The New England journal of medicine.

[201]  W. Rom,et al.  The host immune response to tuberculosis. , 1998, American journal of respiratory and critical care medicine.

[202]  A. Harries,et al.  Prevalence of tuberculosis in TB suspects with short duration of cough. , 1998, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[203]  D. Wilkinson.  Anti-tuberculosis drug resistance in the world: The WHO/IUATLD Global Project on Anti-Tuberculosis Drug Resistance Surveillance. Geneva: World Health Organization, 1997. 228pp. Price Sw. fr 25/US$22.50 (in developing countries Sw. fir 17.50). (Reference WHO/TB/97.229) , 1998 .

[204]  L. P. Ormerod.  Rifampicin and isoniazid prophylactic chemotherapy for tuberculosis , 1998, Archives of disease in childhood.

[205]  L. Reller,et al.  Fatal Mycobacterium tuberculosis bloodstream infections in febrile hospitalized adults in Dar es Salaam, Tanzania. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[206]  P. Barnes,et al.  Chest radiographic findings in patients with tuberculosis with recent or remote infection. , 1997, American journal of respiratory and critical care medicine.

[207]  M. Vjecha,et al.  A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. Uganda-Case Western Reserve University Research Collaboration. , 1997, The New England journal of medicine.

[208]  V. Ritacco,et al.  Nosocomial spread of human immunodeficiency virus-related multidrug-resistant tuberculosis in Buenos Aires. , 1997, The Journal of infectious diseases.

[209]  J. Alberdi,et al.  Isoniazid preventive therapy in human immunodeficiency virus-infected persons. Long-term effect on development of tuberculosis and survival. , 1997, Archives of internal medicine.

[210]  D. Maher,et al.  Screening pulmonary tuberculosis suspects in Malawi: testing different strategies. , 1997, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[211]  I. Onorato,et al.  Asymptomatic hepatitis in persons who received alternative preventive therapy with pyrazinamide and ofloxacin. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[212]  R. Ridzon,et al.  Rifampin preventive therapy for tuberculosis infection: experience with 157 adolescents. , 1997, American journal of respiratory and critical care medicine.

[213]  G. Woody,et al.  Anonymous HIV testing using home collection and telemedicine counseling. A multicenter evaluation. , 1997, Archives of internal medicine.

[214]  D. Gottlieb,et al.  Rifampin preventive therapy for tuberculosis in Boston's homeless. , 1996, American journal of respiratory and critical care medicine.

[215]  J. T. Crawford,et al.  A multi-institutional outbreak of highly drug-resistant tuberculosis: epidemiology and clinical outcomes. , 1996, JAMA.

[216]  S. Salpeter.  Isoniazid preventive therapy. , 1996, Archives of internal medicine.

[217]  K. D. de Cock,et al.  Autopsy‐proven causes of death in HIV‐infected patients treated for tuberculosis in Abidjan, Côte d'lvoire , 1995, AIDS.

[218]  K. D. de Cock,et al.  Radiologic manifestations of pulmonary tuberculosis in HIV-1 and HIV-2-infected patients in Abidjan, Côte d'Ivoire. , 1995, Tubercle and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[219]  D. Vlahov,et al.  Correlates of Hepatitis C Virus Infections among Injection Drug Users , 1995, Medicine.

[220]  D. Enarson.  The International Union Against Tuberculosis and Lung Disease model National Tuberculosis Programmes. , 1995, Tubercle and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[221]  K. D. de Cock,et al.  Response to treatment, mortality, and CD4 lymphocyte counts in HIV-infected persons with tuberculosis in Abidjan, Côte d'Ivoire , 1995, The Lancet.

[222]  H. Gayle,et al.  Impact of the HIV epidemic on trends in tuberculosis in Abidjan, Côte d'Ivoire. , 1995, Tubercle and Lung Disease.

[223]  A. Andrianarisoa,et al.  Acute respiratory infections (A. R. I.) in an outlying health formation: Epidemiology and cares , 1994 .

[224]  M. Diomande,et al.  The mortality and pathology of HIV infection in a West African city , 1993, AIDS.

[225]  T. Quinn,et al.  A clinical and pathological comparison of the WHO and CDC case definitions for AIDS in Kinshasa, Zaïre: is passive surveillance valid? , 1993, AIDS.

[226]  J. Pape,et al.  Effect of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infection , 1993, The Lancet.

[227]  R. Brindle,et al.  Quantitative bacillary response to treatment in HIV-associated pulmonary tuberculosis. , 1993, The American review of respiratory disease.

[228]  R. Hayes,et al.  The impact of human immunodeficiency virus on presentation and diagnosis of tuberculosis in a cohort study in Zambia. , 1993, The Journal of tropical medicine and hygiene.

[229]  K. D. de Cock,et al.  Tuberculosis and HIV infection in sub-Saharan Africa. , 1992, JAMA.

[230]  R. Brindle,et al.  Cohort study of HIV-positive and HIV-negative tuberculosis, Nairobi, Kenya: comparison of bacteriological results. , 1992, Tubercle and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[231]  G. Schoolnik,et al.  An outbreak of tuberculosis with accelerated progression among persons infected with the human immunodeficiency virus. An analysis using restriction-fragment-length polymorphisms. , 1992, The New England journal of medicine.

[232]  M. A. Steele,et al.  Toxic hepatitis with isoniazid and rifampin. A meta-analysis. , 1991, Chest.

[233]  W. Bailey,et al.  Risk factors for isoniazid (NIH)-induced liver dysfunction. , 1981, Journal of clinical gastroenterology.

[234]  D. Snider.  Pyridoxine supplementation during isoniazid therapy. , 1980, Tubercle.

[235]  D. Solomon,et al.  Toxic effects of isoniazid in tuberculosis chemoprophylaxis. Role of biochemical monitoring in 1,000 patients. , 1979, JAMA.

[236]  D. Snider,et al.  Isoniazid-related hepatitis: a U.S. Public Health Service cooperative surveillance study. , 1978, The American review of respiratory disease.

[237]  I. Litt,et al.  Isoniazid hepatitis in adolescents. , 1976, The Journal of pediatrics.

[238]  U. Thorgeirsson,et al.  Acetylation rates and monthly liver function tests during one year of isoniazid preventive therapy. , 1975, Chest.

[239]  W. Bailey,et al.  The effect of isoniazid on transaminase levels. , 1974, Annals of internal medicine.

[240]  G. Comstock,et al.  The prognosis of a positive tuberculin reaction in childhood and adolescence. , 1974, American journal of epidemiology.

[241]  R. Nelson,et al.  Isoniazid toxicity. A prospective study in secondary chemoprophylaxis. , 1972, JAMA.

[242]  G. Comstock,et al.  Isoniazid prophylaxis in Alaskan Boarding schools. A comparison of two doses. , 1969, The American review of respiratory disease.

[243]  J. Smith,et al.  Serum transaminase elevations and other hepatic abnormalities in patients receiving isoniazid. , 1969, Annals of internal medicine.

[244]  K. Lyseng-Williamson,et al.  Tenofovir disoproxil fumarate: a review of its use in the management of HIV infection. , 2005, Drugs.

[245]  R. Hayes,et al.  HIV infection and the duration and control of prevalent tuberculosis disease in Harare, Zimbabwe , 2005 .

[246]  T. Boerma,et al.  HIV-related tuberculosis: how well are we doing with current control efforts? , 2005, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[247]  E. Corbett,et al.  Assessing the impact of HIV on the annual risk of TB infection using a mathematical model , 2005 .

[248]  P. Kaleebu,et al.  48 week virological response to a triple nucleoside/nucleotide analogue regimen in adults with HIV infection in Africa within the DART trial. , 2005 .

[249]  James Curran,et al.  Scaling Up Antiretroviral Therapy in Resource-Limited Settings: Treatment Guidelines for a Public Health Approach , 2005 .

[250]  P. Fujiwara,et al.  Tuberculosis bacteriology--priorities and indications in high prevalence countries: position of the technical staff of the Tuberculosis Division of the International Union Against Tuberculosis and Lung Disease. , 2005, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[251]  A. Harries,et al.  Interim policy on collaborative TB / HIV activities. , 2004 .

[252]  P. Upchurch,et al.  Transmission of Mycobacterium tuberculosis associated with failed completion of treatment for latent tuberculosis infection--Chickasaw County, Mississippi, June 1999-March 2002. , 2003, MMWR. Morbidity and mortality weekly report.

[253]  J. Deeks,et al.  Male circumcision for prevention of heterosexual acquisition of HIV in men. , 2003, The Cochrane database of systematic reviews.

[254]  G. Aldrovandi,et al.  Antiretroviral Pharmacokinetics in the Paediatric Population , 2002, Clinical pharmacokinetics.

[255]  Christopher Dye,et al.  Low access to a highly effective therapy: a challenge for international tuberculosis control. , 2002, Bulletin of the World Health Organization.

[256]  T. Kenyon,et al.  Pathology and causes of death in a group of 128 predominantly HIV-positive patients in Botswana, 1997-1998. , 2002, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[257]  K. Floyd,et al.  Interventions to reduce tuberculosis mortality and transmission in low- and middle-income countries. , 2002, Bulletin of the World Health Organization.

[258]  J. Samet,et al.  Food and Drug Administration , 2007, BMJ : British Medical Journal.

[259]  T. Frieden,et al.  Controlling multidrug-resistant tuberculosis and access to expensive drugs: a rational framework. , 2002, Bulletin of the World Health Organization.

[260]  J. Keane,et al.  Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. , 2001, The New England journal of medicine.

[261]  Tuberculosis control in the era of the HIV epidemic: risk of tuberculosis infection in Tanzania, 1983-1998. , 2001, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[262]  Missed opportunities for prevention of tuberculosis among persons with HIV infection--selected locations, United States, 1996-1997. , 2000, MMWR. Morbidity and mortality weekly report.

[263]  M. Mwasekaga,et al.  Low levels of drug resistance amidst rapidly increasing tuberculosis and human immunodeficiency virus co-epidemics in Botswana. , 1999, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[264]  D. Havlir,et al.  Tuberculosis in patients with human immunodeficiency virus infection. , 1999, The New England journal of medicine.

[265]  R. Chaisson,et al.  Will DOTS do it? A reappraisal of tuberculosis control in countries with high rates of HIV infection. , 1999, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[266]  Reuben Granich,et al.  GUIDELINES FOR THE PREVENTION OF TUBERCULOSIS IN HEALTH CARE FACILITIES IN RESOURCE-LIMITED SETTINGS , 1999 .

[267]  A. Grant,et al.  Natural history and spectrum of disease in adults with HIV/AIDS in Africa. , 1997, AIDS.

[268]  Tuberculosis preventive therapy in HIV-infected individuals. , 1994, Bulletin of the World Health Organization.

[269]  Nosocomial transmission of multidrug-resistant tuberculosis among HIV-infected persons--Florida and New York, 1988-1991. , 1991, MMWR. Morbidity and mortality weekly report.

[270]  Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. International Union Against Tuberculosis Committee on Prophylaxis. , 1982, Bulletin of the World Health Organization.

[271]  I Sutherland,et al.  Recent studies in the epidemiology of tuberculosis, based on the risk of being infected with tubercle bacilli. , 1976, Advances in tuberculosis research. Fortschritte der Tuberkuloseforschung. Progres de l'exploration de la tuberculose.